scholarly journals Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension

2020 ◽  
Vol 10 (5) ◽  
pp. 1675-1685
Author(s):  
Sabrina Schweintzger ◽  
Martin Koestenberger ◽  
Axel Schlagenhauf ◽  
Gernot Grangl ◽  
Ante Burmas ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Receptor Antagonist ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor ◽  
Safety And Efficacy

scholarly journals Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors

2018 ◽  
Vol 4 (1) ◽  
pp. 00079-2017 ◽  
Author(s):  
Todd M. Tartavoulle ◽  
Aryn C. Karpinski ◽  
Andrew Aubin ◽  
Benzi M. Kluger ◽  
Oliver Distler ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Pulmonary Hypertension ◽  
Receptor Antagonist ◽  
Body Mass ◽  
Phosphodiesterase Inhibitor ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor ◽  
Physical Fatigue ◽  
General Fatigue ◽  
Reduced Activity

Pulmonary hypertension is a potentially fatal disease. Despite pharmacological advances in pulmonary hypertension, fatigue remains common in patients with pulmonary hypertension.A convenience sample of 120 participants at an international patient conference completed the Multidimensional Fatigue Inventory (MFI)-20 scale. Data on New York Heart Association Functional Class, body mass index, oxygen use and medication type/use were also collected.There was a high prevalence of “severe” to “very severe” fatigue for each dimension: General Fatigue (60%), Physical Fatigue (55.8%), Reduced Activity (41.7%), Reduced Motivation (32.5%) and Mental Fatigue (27.5%). The mean±sd overall MFI-20 score was 58±5.1. Dimensions with the highest averaged levels were General Fatigue (13.40±3.61), Physical Fatigue (13.23±3.67) and Reduced Activity (11.33±4.16). Body mass index correlated with higher fatigue scores. Phosphodiesterase inhibitor plus endothelin receptor antagonist combination negatively predicted General Fatigue, Physical Fatigue, Reduced Motivation and Reduced Activity. Triple therapy was a significant predictor of General Fatigue, Physical Fatigue and Reduced Activity. There were no significant predictors of Mental Fatigue.Multidimensional fatigue is common and severe in patients with pulmonary hypertension. Phosphodiesterase inhibitor plus endothelin receptor antagonist combination resulted in lower scores in most fatigue dimensions. Comprehensive assessment of fatigue should be considered in the clinical care of patients with pulmonary hypertension and clinical research to develop formal interventions that target this disabling symptom.

Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan

2010 ◽  
Vol 170 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Stephan Schroll ◽  
Michael Arzt ◽  
Daniela Sebah ◽  
Martin Nüchterlein ◽  
Friedrich Blumberg ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Fibrosis ◽  
Receptor Antagonist ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor
Sign in / Sign up

Export Citation Format

Share Document